CSO, Wesley Jackson, Ph.D., share a company overview describing Valitor’s platform technology and pipeline in a presentation at the @HCWCO 6th Annual Ophthalmology Virtual Conference on Wed, July 22, 2026 at 4:00 p.m. ET.
Listen to the presentation here: bit.ly/4aMSrXU
Don’t miss Valitor Director of Development, Livia Wilz Brier, Ph.D., present at the 9th Annual Ophthalmology Innovation Source (OIS) Retina Innovation Summit.
The Valitor presentation will take place on Tues, July 14, 2026, at 10:50 a.m. ET
Learn more: bit.ly/4arnyYQ
Chief Executive Officer Greg Kunst will discuss the latest company updates in a fireside chat at the 2026 @Piper_Sandler Virtual Ophthalmology Symposium on July 10, 2026 at 9:00 a.m. ET.
Be sure to check out the discussion if you’re attending the conference.
CEO Greg Kunst will share a company overview describing Valitor’s platform technology and pipeline at the AECOS 2026 Summer Symposium on Wed, July 9th at 1:22 p.m. MT.
Check out the panel if you’re attending the symposium.
bit.ly/447FiVy
CSO, Wesley Jackson, Ph.D., will join other industry experts in a panel discussion at the Ophthalmology Tech Forum on Friday, June 26, 2026 at 2:30 p.m. PT.
Check out the panel discussion if you’re in attendance.
Learn more: bit.ly/4vVnyZs
CFO Peter F. Lang, and CMO Michael Goldstein, M.D., will attend the Evercore Private Company Conference and participate in the ophthalmology panel on June 24, 2026 at 8:40 a.m. ET.
Be sure to check out the panel if you’re attending the conference.
#ICYMI: Watch the latest video from @RetinalPhys where Director of Development, Livia Wilz Brier, Ph.D., gives an overview of her recent #ARVO2026 oral presentation highlighting the potential of VLTR-559 to treat Wet AMD.
Watch the full video here: bit.ly/3P2IPk2
We presented preclinical data demonstrating the superior durability, efficacy & safety profile of VLTR-559 to treat wet-AMD at #ARVO2026. Data reinforces the potential of VLTR-559 to transform the treatment landscape & reduce treatment burden for patients.
bit.ly/4dnosY0
Chief Scientific Officer, Wesley Jackson, Ph.D., will join other industry experts in a panel discussion at Eyecelerator @ ARVO 2026 on Friday, May 1, 2026 at 2:50 p.m. MT.
Check out the panel discussion if you’re in attendance.
Learn more: bit.ly/3OIGpqC
CEO Gregory D. Kunst will share a company overview describing our platform technology and pipeline in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Mon, Apr 13, 2026 at 2:15 p.m. ET. Listen to the live or archived discussion:valitorbio.com/#events
We’re excited to announce that a preclinical abstract highlighting the potential of VLTR-559 to treat wet AMD, has been accepted for oral presentation at the ARVO Annual Meeting taking place May 3-7,2026 in Denver, CO.
Learn more: bit.ly/3OqDqCU
On Tues, Feb 24th at 2:00 p.m. PT, CEO Greg Kunst will present a company overview & host investor one-on-one meetings at the Biocom Global Partnering and Investor Conference. If you will be attending the conference, we welcome the opportunity to connect!
bit.ly/4aqiV1A
During #AMD & #LowVisionAwarenessMonth, we recognize the millions living with visual impairment.
We’re committed to advancing our MVP technology platform for vision-threatening diseases, including wet #AMD. Learn more about vision rehabilitation resources: bit.ly/4rg5YwZ
Chief Scientific Officer, Wesley Jackson, Ph.D., will join other ophthalmology experts in a panel discussion and a seminar at the 4th Annual Ophthalmic Drug Delivery Summit taking place Jan 27-29, 2026, in San Francisco, CA. Learn more: bit.ly/4qzwaCt
Season’s Greetings from Valitor!
We’re thankful for the continued support as we pursue innovative ophthalmic medicines aimed at improving vision and transforming patient care.
Wishing you a joyful holiday season and a bright year ahead.
#HappyHolidays
CEO Gregory D. Kunst will join fellow ophthalmic drug development leaders at BTIG’s 5th Annual Ophthalmology Day on Mon, Dec 1, 2025, to discuss emerging innovation in ophthalmology. Greg will also be available for one-on-one investor meetings.
Valitor CEO Gregory D. Kunst, will review preclinical data highlighting the potential of VLTR-559 in a presentation at the 15th Annual @OISTWEETS Ophthalmology Innovation Summit taking place Nov 21-22, 2025 in San Diego, CA.
Learn more: bit.ly/3LS1Q6I
#OIS2025
At #Eyecelerator, we shared preclinical data showing VLTR-559 supports potential 6-month dosing for wet AMD, with a longer ocular half-life and sustained retinal exposure vs current anti-VEGF therapies.
Learn more: bit.ly/3IWwsD7
We’re excited to welcome Gregory D. Kunst as CEO of Valitor!
A seasoned leader in biotech and ophthalmology, Greg will be instrumental as we advance VLTR-559, our long-acting anti-VEGF therapy for wet AMD, into clinical studies.
bit.ly/46ZTlPi
